BioSig Executes Agreement with Bellin Health for the Acquisition of its PURE EP™ Technology
Westport, CT, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Leading Midwest healthcare system reports significant cost savings and noise reduction following...
Healthcare
Veru Announces Appointment of Dr. David D. Ho as Chairman of its Infectious Disease Scientific Advisory Board
MIAMI. FL, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines...
Biomerica Appoints Mayo Clinic Gastroenterologist, Dr. Brian E. Lacy, to the Company’s Scientific Advisory Board
Dr. Lacy is the former co-Editor in Chief of the American Journal of Gastroenterology, the former Editor in Chief of...
Ceapro to Present at the Virtual Investor 2023 Companies to Watch Event
Live video webcast on Wednesday, January 18th at 3:00 PM ETEDMONTON, Alberta, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Ceapro Inc....
Helsinn closes financing agreement with Oberland Capital
Helsinn closes financing agreement with Oberland Capital Funding secured to expand the portfolio of late- and commercial-stage oncology and rare...
BioAtla Provides Clinical Program Updates and Upcoming 2023 Milestones
Mecbotamab vedotin (BA3011) Phase 2 part 1 interim results in PD-1 failure NSCLC continues to show strong antitumor activity in...
Solid Biosciences Outlines Strategy for Leadership in Precision Genetic Medicines with Focus on Neuromuscular and Cardiac Diseases
– Investigational New Drug (IND) application for SGT-003, next-generation gene therapy for Duchenne muscular dystrophy utilizing novel capsid AAV-SLB101, expected in...
Sharps Technology Inc. to Introduce New Specialized Prefillable Syringe Systems in 2023
High-Value specialized prefillable syringe systems to accelerate revenue growth in 2023 and beyond Company to launch next generation specialty polymer-based...
Vericel Announces Preliminary Fourth-Quarter and Full-Year 2022 Financial Results and Accelerated Launch Timeline for MACI Arthroscopic Program
Full-Year Total Revenue Expected to be Approximately $164 to $165 Million MACI Full-Year Revenue Expected to be at the High...
Indegene expands Europe presence with new center in Germany to enable life sciences companies be future ready
FRANKFURT, Germany and PRINCETON, N.J. and BANGALORE, India, Jan. 10, 2023 (GLOBE NEWSWIRE) -- Indegene, a digital-first, life sciences commercialization...
Amarin Provides Preliminary Fourth Quarter and Full Year 2022 Revenue and Cash Position and Priorities for 2023
-- Company Delivers Fourth Consecutive Quarter of U.S. Revenue Stabilization, Positive Fourth Quarter Cash Flow and Continued Progress on European...
Helius Medical Technologies, Inc. Announces Participation of Neurology Center of New England in its Therapeutic Experience Program
-- Fifth Center of Excellence added in multi-center, company-sponsored, open label observational interventional trial to evaluate the impact of subjects’...
Sernova and Evotec on Track to Initiate Clinical Testing of the First iPSC-Derived Islets in Cell Pouch as a Potential Functional Cure for Type 1 Diabetes
First iPSC-derived commercially viable off-the-shelf islet combination product is advancing towards regulatory filing in 2024 for anticipated clinical trial authorization...
Kymera Therapeutics Shares Key 2023 Goals to Support its Evolution into a Fully Integrated Degrader Medicines Company
WATERTOWN, Mass., Jan. 10, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein...
Prenetics Owned ACT Genomics Receives FDA Clearance for ACTOnco, the First Asia-Based Company to Receive Clearance for a Comprehensive Genomic Profiling Test for All Solid Tumors
Prenetics has completed the majority stake acquisition of ACT Genomics to spearhead its entry into to the US$80+ billion global...
Annexon Highlights Strategic Focus to Advance Four Flagship Complement Programs through Late-Stage Development and Progress Across Three Therapeutic Franchises
Mid-stage and Pivotal Trials of ANX005, ANX007 and ANX1502 Poised to Achieve Numerous Catalysts in Multiple Disease Indications Well-Capitalized with...
Merus Provides 2023 Outlook
- As of year-end 2022, more than 150 patients with NRG1 gene fusion positive (“NRG1+”) cancer have been treated with...
OpGen Announces Pricing of $7.5 Million Public Offering
ROCKVILLE, Md., Jan. 06, 2023 (GLOBE NEWSWIRE) -- OpGen, Inc. (Nasdaq: OPGN, “OpGen” or “the Company”), a precision medicine company...
Madrigal Announces Additional Positive Results from the Pivotal Phase 3 MAESTRO-NASH Clinical Trial of Resmetirom for the Treatment of NASH with Liver Fibrosis
As previously reported, resmetirom demonstrated improvements in NASH and liver fibrosis on liver biopsies, the primary endpoints of the MAESTRO-NASH...
Novan Submits New Drug Application to the U.S. FDA for Berdazimer Gel, 10.3% (SB206) for the Treatment of Molluscum Contagiosum
– Potential FDA approval anticipated in first quarter 2024, assuming the filing is accepted by the FDA and under standard...